Iovance Biotherapeutics (IOVA) Financials

$10.98

$0.18 (1.62%)

As on 25-Sep-2026 13:37EDT

Market cap

$4,643 Mln

Revenue (TTM)

$325 Mln

P/E Ratio

--

P/B Ratio

6.3

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	324.97	263.50	164.07	1.19	0.24	--
Cost of Revenue	-52.97	7.29	124.00	10.76	21.14	13.98
Gross Profit	377.94	256.22	40.08	-9.57	-21.14	-13.98
Operating Expenses	679.25	659.57	435.35	450.99	398.88	342.70
Operating Profit (EBIT)	-301.31	-403.36	-395.28	-460.56	-398.88	-342.70
Other Income	--	--	--	--	--	0.45
Profit before Tax	-293.78	-393.05	-375.01	-447.52	-395.89	-342.25
Provision for Tax	-4.26	-2.07	-2.83	-3.48	-5.97	-14.43
Profit after Tax (Net Income)	-289.52	-390.98	-372.18	-444.04	-389.92	-327.82
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-395.89	-342.25

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	736.05	698.58	710.41	584.61	499.64	621.66
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	72.64	76.23	77.68	85.43	72.86	66.47
Current Liabilities	106.85	138.36	122.34	110.31	91.49	89.20
Total Liabilities	1,022.38	913.17	910.43	780.35	663.98	777.33

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	451.27	470.48	453.41	472.50	184.87	269.38
Current Assets	464.26	442.69	457.02	307.85	479.12	507.96
Total Assets	1,022.38	913.17	910.43	780.35	663.98	777.33
Total Debt*	46.00	48.44	58.26	75.86	85.45	71.53
Net Current Assets	357.41	304.33	334.68	197.54	387.63	418.76

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-302.41	-352.98	-361.82	-292.76	-227.94
Cash Flow from Investing Activities	--	47.50	-96.41	-155.24	256.46	0.13
Cash from Financing Activities	--	300.77	390.66	462.96	190.15	239.27
Net Cash Inflow / Outflow	--	--	--	--	--	11.46

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.72	-0.96	-1.22	-1.73	-2.37	-2.09
Cash EPS ($)	--	-0.84	-1.08	-1.62	-2.24	-2.00
Adjusted Book Value ($)	--	1.72	2.33	2.28	3.03	3.96
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.74	-1.16	-1.41	-1.78	-1.45
Free Cash Flow per Share ($)	--	-0.83	-1.19	-1.50	-1.90	-1.69

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-51.59	-52.08	-71.30	-61.01	-46.79
ROE (%)	-40.36	-55.50	-57.48	-81.91	-69.55	-51.30
ROA (%)	-28.12	-42.88	-44.02	-61.49	-54.11	-42.41
EBIT Margin (%)	-90.40	-149.16	-228.56	-37,638.02	-167,595.80	--
Net Margin (%)	-89.09	-148.38	-226.84	-37,345.42	-163,833.19	-72,687.58
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	34.55	0.61	136.99	4.00	--	--
EBIT Growth (%)	25.39	-4.81	16.20	-12.19	-16.39	-30.83
Net Profit Growth (%)	25.75	-5.05	16.18	-13.88	-18.94	-26.29
EPS Growth (%)	41.20	0.21	0.30	0.27	-0.13	-0.18
Book Value Growth (%)	-21.70	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-2.84	-6.06	-4.69	-2.70	-9.14
Price / Book Value	6.27	1.59	3.18	3.56	2.11	4.82
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-8.68	-2.42	-6.01	-4.53	-1.76	-7.80
Close Price ($)	4.16	2.73	7.40	8.13	6.39	19.09
High Price ($)	5.63	8.15	18.33	9.36	20.05	54.21
Low Price ($)	1.67	1.64	7.05	3.21	5.42	15.88
Market Cap ($ Cr)	4,642.96	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.07	0.08	0.13	0.17	0.12
Short term debt to equity ratio	0.00	0.01	0.02	0.01	0.03	0.01
Current Ratio	4.35	3.20	3.74	2.79	5.24	5.69
Quick Ratio	3.82	2.83	3.31	2.70	5.24	--
Interest Coverage	--	--	--	--	-133.63	-759.87

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	31.42	31.29	42.26	12.70	--	--
Asset Turnover	0.32	0.29	0.19	0.00	0.00	--
Receivable days	--	105.20	77.35	23.19	--	--
Inventory Days	--	2,586.68	91.16	176.12	--	--
Payable days	--	1,244.94	89.30	1,014.18	466.43	534.16
Cash Conversion Cycle	--	1,446.94	79.21	-814.86	-466.43	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.